Form 4: Hinge Health CEO Sells Shares Under 10b5-1 Plan

Hinge Health CEO Daniel Antonio Perez reported the sale of 166,665 Class A Common Stock shares on January 5, 2026, executed under a pre-arranged 10b5-1 trading plan.

Summary

• Daniel Antonio Perez, CEO & Co-Founder, Director, and 10% Owner of Hinge Health, Inc., reported transactions on January 5, 2026.
• Converted 166,665 shares of Class B Common Stock into an equal number of Class A Common Stock.
• Subsequently sold 122,368 shares of Class A Common Stock at a weighted average price of $46.2458 per share, with prices ranging from $45.47 to $46.46.
• Sold an additional 44,297 shares of Class A Common Stock at a weighted average price of $46.7664 per share, with prices ranging from $46.47 to $46.97.
• All sales were conducted pursuant to a Rule 10b5-1 trading plan adopted on September 11, 2025.
• Following these transactions, direct beneficial ownership of Class A Common Stock is 0 shares, while direct beneficial ownership of Class B Common Stock is 14,376,762 shares.
• Indirect beneficial ownership (by spouse) includes 35,470 Class A Common Stock and 515,705 Class B Common Stock.

Sentiment

Score: 5

Explanation: Neutral. While an insider sale can be seen negatively, the execution under a pre-arranged 10b5-1 plan mitigates concerns about opportunistic timing based on non-public information. It's a routine disclosure for planned liquidity events.

Positives

• The sales were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned divestment rather than a reaction to new, non-public information.

Negatives

• A significant insider sale by the CEO, Director, and 10% owner could be perceived negatively by some investors, even if pre-planned.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may interpret the CEO's sale of shares as a signal, though the 10b5-1 plan suggests it's for personal financial planning rather than a lack of confidence in the company.

Key Dates

Recommendation

The reported transactions are routine insider sales executed under a pre-arranged 10b5-1 trading plan. This type of transaction is generally not indicative of a change in the company's fundamental outlook or management's confidence, as it's often for personal financial planning or diversification. Therefore, it does not provide a strong basis for a 'buy' or 'sell' recommendation, suggesting a 'hold' position for existing investors.

Keywords

Hinge Health, HNGE, Insider Trading, Form 4, Stock Sale, CEO, Daniel Antonio Perez, 10b5-1 Plan, Class A Common Stock, Class B Common Stock